Begriffe & Kennungen
Begriff oder HOS-ID gezielt finden. Die alphabetische Liste können Sie seitenweise durchblättern.
121.734 Begriffe
Apixaban Accord · 4.8 · 48 Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows
HOS-146712Apixaban Accord · 4.8 · Blood and lymphatic system disorders Anaemia Common Common Common Thrombocytopenia Uncommon Common Common Immu
HOS-146699Apixaban Accord · 4.8 · Common adverse reactions were haemorrhage, contusion, epistaxis, and haematoma (see Table 3 for adverse reacti
HOS-146653Apixaban Accord · 4.8 · Common adverse reactions were haemorrhage, contusion, epistaxis, and haematoma (see Table 3 for adverse reacti
HOS-146693Apixaban Accord · 4.8 · In paediatric patients, epistaxis (very common), abnormal vaginal haemorrhage (very common), hypersensitivity
HOS-146667Apixaban Accord · 4.8 · In the NVAF studies, the overall incidence of adverse reactions related to bleeding with apixaban was 24.3% in
HOS-146655Apixaban Accord · 4.8 · In the NVAF studies, the overall incidence of adverse reactions related to bleeding with apixaban was 24.3% in
HOS-146694Apixaban Accord · 4.8 · In the VTEp studies, in total, 11% of the patients treated with apixaban 2.5 mg twice daily experienced advers
HOS-146654Apixaban Accord · 4.8 · In the VTEt studies, the overall incidence of adverse reactions related to bleeding with apixaban was 15.6% in
HOS-146695Apixaban Accord · 4.8 · Investigations Occult blood positive Uncommon Uncommon Not known Injury, poisoning and procedural complication
HOS-146704Apixaban Accord · 4.8 · Nervous system disorders Brain haemorrhage† Uncommon Rare Not known Eye disorders Eye haemorrhage (including C
HOS-146700Apixaban Accord · 4.8 · Overall, the safety profile of apixaban in paediatric patients 28 days to < 18 years of age was similar to tha
HOS-146665Apixaban Accord · 4.8 · Overall, the safety profile of apixaban in paediatric patients 28 days to < 18 years of age was similar to tha
HOS-146708Apixaban Accord · 4.8 · Paediatric population
HOS-146663Apixaban Accord · 4.8 · Paediatric population
HOS-146706Apixaban Accord · 4.8 · Reporting of suspected adverse reactions
HOS-146711Apixaban Accord · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
HOS-146669Apixaban Accord · 4.8 · Summary of the safety profile In adults, the safety of apixaban has been investigated in 7 Phase III clinical
HOS-146692Apixaban Accord · 4.8 · Summary of the safety profile In adults, the safety of apixaban has been investigated in 7 Phase III clinical
HOS-146652Apixaban Accord · 4.8 · Table 3: Tabulated adverse reactions System organ class Prevention of Prevention of Treatment of Treatment of
HOS-146659Apixaban Accord · 4.8 · Table 3: Tabulated adverse reactions System organ class Prevention of stroke and Treatment of Treatment of sys
HOS-146698Apixaban Accord · 4.8 · Tabulated list of adverse reactions Table 3 shows the adverse reactions ranked under headings of system organ
HOS-146657Apixaban Accord · 4.8 · Tabulated list of adverse reactions Table 3 shows the adverse reactions ranked under headings of system organ
HOS-146696Apixaban Accord · 4.8 · The frequencies of adverse reactions reported in Table 3 for paediatric patients are derived from study CV1853
HOS-146658Apixaban Accord · 4.8 · The frequencies of adverse reactions reported in Table 3 for paediatric patients are derived from study CV1853
HOS-146697Apixaban Accord · 4.8 · The most commonly reported adverse reactions in paediatric patients were epistaxis, and abnormal vaginal haemo
HOS-146666Apixaban Accord · 4.8 · The most commonly reported adverse reactions in paediatric patients were epistaxis, and abnormal vaginal haemo
HOS-146709Apixaban Accord · 4.8 · The safety of apixaban has been investigated in 1 Phase I and 3 Phase II/III clinical studies including 970 pa
HOS-146664Apixaban Accord · 4.8 · The safety of apixaban has been investigated in 1 Phase I and 3 Phase II/III clinical studies including 970 pa
HOS-146707Apixaban Accord · 4.8 · The use of apixaban may be associated with an increased risk of occult or overt bleeding from any tissue or or
HOS-146662